Opendata, web and dolomites

PAPRAT SIGNED

PAPRAT (Predictive Algorithm for Pre-Rheumatoid Arthritis Treatment). The new and most efficient multiple biomarkers-based system for an early selection of RA treatment intensity

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PAPRAT project word cloud

Explore the words cloud of the PAPRAT project. It provides you a very rough idea of what is the project "PAPRAT" about.

accuracy    addressable    classify    burden    index    leave    launch    acpa    classifying    3m    trl6    joints    lack    45    efficient    delays    reduce    biomarker    variables    optimize    prepare    drivers    degenerative       treatment    bone    outcome    grow    suffering    aggressive    combined    citrullinated    proper    pain       unclassified    spanish    validate    once    complications    rheumatoid    genetic    yearly    markers    discerning    personalized    17    good    economic    poorly    multiple    deterioration    ra    world    prognostics    accurate    blood    unnecessary    critical    organs    algorithm    few    bn    start    therapy    licensing    dmards    health    service    82    designed    total    ageing    arthritis    software    genomic    demographical    disability    combines    spent    biological    complete    predictive    genetics    paprat    platform    antibodies    finished    medicine    patients    deformity    continued    severity    40    rf    market    difficult    clinical    disease    population    globally    protein    calculate    remission    medium    epigenetic    needing    anti    administration    biosimilars    prognosis   

Project "PAPRAT" data sheet

The following table provides information about the project.

Coordinator
MAKING GENETICS S.L. 

Organization address
address: PLAZA CEIN 1, POLIGONO MOCHOLI, OFICINA R1.9, NOAIN
city: NOAIN
postcode: 31110
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MAKING GENETICS S.L. ES (NOAIN) coordinator 50˙000.00

Map

 Project objective

Rheumatoid arthritis (RA) affects 1% of world population (17.6 M) and it is a relevant economic burden (€45 Bn spent yearly in Europe). It is a degenerative disease that affects bone health, cause joints’ deformity, impact other organs and cause disability. An early and personalized treatment can greatly improve its outcome, achieve remission and reduce pain, thus an accurate prognosis is critical for its efficient management. However, this is difficult for the lack of good prognosis factors (currently rheumatoid factor-RF or anti-citrullinated protein antibodies-ACPA), which at present are very few, poorly accurate and leave 40% of patients unclassified (suffering health complications due to an unnecessary aggressive treatment or from deterioration due to delays in proper treatment). Making Genetics is a Spanish start-up focused in personalized medicine through genomic approaches. We have designed and developed a prognostics test for RA based on a blood test and the use of our new PAPRAT algorithm, with 82.4% accuracy. PAPRAT is a multiple biomarker-based system capable of classifying pre-rheumatoid arthritis patients, discerning which will need a more aggressive treatment. It combines unique genomic markers (genetic and epigenetic), as well as clinical and demographical variables, to calculate a predictive index and classify patients’ RA severity as HIGH (needing early administration of a combined therapy with biological DMARDs) or LOW and MEDIUM (non-biological DMARDs are enough). It is at a TRL6 and now we aim to optimize it, further validate it, develop a software platform and prepare its market launch. RA is expected to grow by drivers such as an ageing population or the continued uptake of biosimilars, and we have currently a total addressable market of 17.6 M patients globally and of around 3M in Europe. We will offer a complete prognosis service, including the blood testing, as well as the licensing of our software platform once it is finished.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PAPRAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PAPRAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More